Feasibility of salvage cord blood transplantation following fludarabine, melphalan and low-dose TBI for graft rejection after hematopoietic stem cell transplantation Bone Marrow Transplantation (2016) 51, 985-987; doi:10.1038/ bmt.2016 published online 15 February 2016 Graft failure (GF) in allogeneic hematopoietic stem cell transplantation (SCT) is a life-threatening complication because patients are at high risk of severe infection during prolonged neutropenia and also experience organ toxicity due to previous transplantation. Graft rejection is a major cause of graft failure, and is caused by the immune response of the recipient against the immunohematopoietic cells of the donor.
Graft failure (GF) in allogeneic hematopoietic stem cell transplantation (SCT) is a life-threatening complication because patients are at high risk of severe infection during prolonged neutropenia and also experience organ toxicity due to previous transplantation. Graft rejection is a major cause of graft failure, and is caused by the immune response of the recipient against the immunohematopoietic cells of the donor. 1, 2 Cord blood is an important source for salvage transplantation because of its prompt availability and less stringent HLA compatibility. However, cord blood transplantation (CBT) has a risk of prolonged neutropenia and recurrence of GF. Previous studies reported that the rate of neutrophil engraftment of salvage CBT is 58% and the overall survival is 28-33%; the major cause of death was treatment-related mortality (TRM) in 61% cases, especially due to infection (65% of the cases of TRM). 3, 4 In cases of immune-associated graft rejection, it is thought that patients should receive reconditioning to efficiently suppress recipient-derived immunity. Considering that fludarabine, melphalan and low-dose TBI conditioning efficiently suppress alloreactive host immunity and ensure engraftment, 5 we have performed salvage CBT following this regimen for patients with graft rejection. We carefully assessed infectious complications before salvage CBT because they may be strongly associated with TRM as carryover infections, leading to death after salvage CBT.
The retrospective analysis included eight consecutive patients with distinct hematological diseases, who developed primary or secondary GF following SCT between April 2004 and May 2015 at Kyoto University Hospital. The patients received a salvage CBT following a fludarabine-based regimen. All participants signed an informed consent form to receive therapy. This study was approved by the Institutional Review Board of Kyoto University Hospital in Japan. Patient characteristics are summarized in Table 1 . Six patients had advanced disease, except for two patients (Nos. 5 and 6) with AML with a CR status. The median age of the patients was 44 years (range, 18-61 years) at the time of GF. The stem cell sources of the failed transplants were unrelated cord blood in five patients and unrelated bone marrow in three patients (Nos. [6] [7] [8] . The regimens of the failed transplants were ablative conditioning in three patients (Nos. 2, 5 and 6). Six patients had primary GF, whereas two patients (Nos. 7 and 8) had secondary GF. Chimerism analysis showed complete recipient chimerism at diagnosis of primary GF (except one patient, with recipient-dominant 492%) and rapid replacement with recipient cells at diagnosis of secondary GF, which suggested immunologically mediated graft rejection.
Characteristics and results of salvage CBT are described in Table 1 . The interval from failed transplantation to salvage transplantation was 44 days in primary GF. The intensity of salvage regimen was similar to that used in de novo CBT. 6 We have recommended a sufficient dose of fludarabine and melphalan as an alkylator and low-dose TBI to ensure engraftment. Two patients Seven patients achieved neutrophil engraftment and platelet recovery following salvage CBT. The median periods of neutrophil recovery and platelet recovery were 20 days (range, 14-22 days) and 33 days (range, 24-52 days), respectively. Seven patients with engraftment achieved complete chimerism in the bone marrow until day 30 after salvage transplantation. One patient (No. 3) achieved 490% second-donor chimerism and platelet recovery but did not achieve neutrophil recovery. One patient (No. 2) did not achieve platelet recovery probably owing to uncontrolled EBV infection.
Six patients had grade 1-2 organ toxicity (pneumonitis, creatinine and mucositis by CTCAE ver. 4.0, Tokyo, Japan) before salvage CBT. All patients tolerated the salvage regimen well: one patient (No. 6) developed grade 3 diarrhea probably owing to melphalan therapy. Although grade 2-3 acute GvHD was observed in two patients (Nos. 7 and 8), the remaining patients had grade 0-1 acute GvHD. Chronic GvHD was observed in two of the five patients evaluated (Nos. 6 and 7). Five patients survived at a median follow-up of 1652 days (range, 184-3991 days). At the last follow-up, three patients with leukemia were alive and in remission, and two patients with aplastic anemia were alive and showed a complete response. Patient No. 4 developed a relapse of AML 760 days after salvage CBT and achieved leukemia remission after re-transplantation.
We focused on the infectious complications that occurred before salvage CBT and assessed the clinical courses ( Figure 1 ). Patient No. 1 developed sepsis (due to Klebsiella pneumoniae) after the first transplantation and received combined antibiotic therapy. He had a slight autorecovery of leukocyte and experienced controllable infection in response to the fluctuating leukocyte counts. He received salvage CBT at the time of clinical remission of the infection. He achieved engraftment and overcame the infectious complication although sepsis recurred on day 10 after salvage CBT. Patient No. 5 developed sepsis (due to Streptococcus mitis) after the first transplantation. He had a partial clinical remission of sepsis in a transient slight recovery of leukocytes, probably of mixed type, during days 10-16, when he experienced a GvH-like reaction (skin eruption and fluid retention). Subsequently, the patient developed GF with bone marrow recipient chimerism levels of 92% on day 19, with the symptoms resolving. He achieved engraftment after salvage CBT although he experienced a recurrence of febrile neutropenia. Patient No. 7 developed grade 2 hemorrhagic cystitis (due to BK virus) after engraftment of the first transplant. Interestingly, she developed secondary GF with remission of hemorrhagic cystitis, suggesting recovery of recipient immunity against viral infection.
After engraftment of salvage CBT, she experienced cystitis, as expected, and was successfully treated with cidofovir. The remaining patients with successful engraftment presented with bacteremia, pulmonary mycosis or febrile neutropenia before salvage CBT, and underwent reconditioning with intensive antibiotic therapy under controlled conditions. In contrast to the patients treated successfully, patient No. 3 developed carryover infection, pneumonia (due to Burkholderia cepacia) and CMV viremia. He did not achieve neutrophil engraftment (donor-dominant 490%) and developed fatal hemorrhagic pneumonia and CMV encephalitis.
This study suggests two clinical implications for the management of GF. First, salvage CBT following conditioning with fludarabine, melphalan and low-dose TBI has an efficient immunosuppressive effect to ensure engraftment, and is feasible for patients with graft rejection. The adverse effects were tolerable in all the patients evaluated. The interval from failed transplantation to salvage transplantation was much shorter than the interval that previous studies suggested was associated with better outcomes, 7, 8 indicating that this regimen may be tolerable in the early phase of primary GF. Moreover, the patients with high-risk aplastic anemia (history of frequent transfusions and refractoriness to immunosuppressive therapy) sustain remission for long durations. Consecutive salvage conditioning following conventional immunosuppressive conditioning for failed transplantation may help to suppress the residual alloreactive immunity and sustain donor hematopoiesis. We did not report the superiority of melphalan as an alkylator in this case series. However, considering the difficulties in conducting prospective controlled trials in the clinical setting, melphalan-combined regimens may be a preferable option for patients who receive other alkylator-combined regimens in failed transplantation. Previous case series reported the promising results of salvage CBT following a 1-day regimen, which is presumed to be the minimum intensity conditioning to shorten the neutropenic period and ensure engraftment. [9] [10] [11] However, this shortened conditioning may require careful clinical management because the intensity of reconditioning was largely dependent on the discretion of attending physician. The intensity of conditioning necessary for donor cell engraftment needs to be investigated in-depth by time course analysis of chimerism and immunocompetent cells. 2, 12 Second, infectious complications before salvage transplantation may be the problem that needs to be addressed with highest priority. The successful patients had managed to attain clinical remission of the infection with intensive antibiotic therapy before salvage CBT. Clinical remission of infection before salvage CBT increases the rate of engraftment and the chance to overcome this poor condition even if the infection recurs after salvage CBT. We believe that determining whether infection before salvage CBT is controllable or uncontrollable can be important to solve this complication. In cases in which infection is controllable, patients should receive reconditioning immediately after reaching an improvement in the infection status. When patients have an uncontrollable infection, extensive treatment including granulocyte transfusion and adoptive T-cell therapy may be needed, [13] [14] [15] as supported by the fact that the transient recovery of leukocytes derived from either recipient or donor was useful to control the infection during leukocytopenia in this study.
In conclusion, this study suggests the feasibility of salvage CBT following this regimen in patients with graft rejection. However, further studies aimed at managing severe infection before salvage CBT to improve the outcomes are required. 
